https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41921 p = 0.0007). Studies of other clinical decision support systems and heparin monitoring systems did not demonstrate improved safety, and quality findings were inconsistent. Systematic education and feedback programs were not efficacious. Conclusions: There is currently insufficient high-quality evidence to recommend any reviewed intervention, though several warrant closer evaluation. Adequately powered controlled trials assessing safety outcomes and evidence-based quality markers in high-risk patient groups and studies of interventions to improve safety of LMWH and DOAC prescribing are needed.]]> Tue 16 Aug 2022 09:02:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46000  C and ABCB1_c.3435C > T were included in the final model, whereby CLSN38 reduced from 76.8 to 55.1%. Conclusion: The identified UGT1A3_c.31 T > C and ABCB1_c.3435C > T variants, from wild type to homozygous, were included in the final model for SN38 clearance.]]> Tue 08 Nov 2022 16:32:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7880 Sat 24 Mar 2018 08:41:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1206 Sat 24 Mar 2018 08:28:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47953 Mon 13 Feb 2023 14:06:54 AEDT ]]>